543 related articles for article (PubMed ID: 30074407)
1. Design of non-inferiority randomized trials using the difference in restricted mean survival times.
Weir IR; Trinquart L
Clin Trials; 2018 Oct; 15(5):499-508. PubMed ID: 30074407
[TBL] [Abstract][Full Text] [Related]
2. Handling an uncertain control group event risk in non-inferiority trials: non-inferiority frontiers and the power-stabilising transformation.
Quartagno M; Walker AS; Babiker AG; Turner RM; Parmar MKB; Copas A; White IR
Trials; 2020 Feb; 21(1):145. PubMed ID: 32029000
[TBL] [Abstract][Full Text] [Related]
3. A comparison of different population-level summary measures for randomised trials with time-to-event outcomes, with a focus on non-inferiority trials.
Quartagno M; Morris TP; Gilbert DC; Langley RE; Nankivell MG; Parmar MK; White IR
Clin Trials; 2023 Dec; 20(6):594-602. PubMed ID: 37337728
[TBL] [Abstract][Full Text] [Related]
4. Conversion of non-inferiority margin from hazard ratio to restricted mean survival time difference using data from multiple historical trials.
Chen R; Basu S; Meyers JP; Shi Q
Stat Methods Med Res; 2022 Oct; 31(10):1819-1844. PubMed ID: 35642291
[TBL] [Abstract][Full Text] [Related]
5. Choosing and changing the analysis scale in non-inferiority trials with a binary outcome.
Li Z; Quartagno M; Böhringer S; van Geloven N
Clin Trials; 2022 Feb; 19(1):14-21. PubMed ID: 34693789
[TBL] [Abstract][Full Text] [Related]
6. Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations.
Eaton A; Therneau T; Le-Rademacher J
Clin Trials; 2020 Jun; 17(3):285-294. PubMed ID: 32063031
[TBL] [Abstract][Full Text] [Related]
7. Study duration for three-arm non-inferiority survival trials designed for accrual by cohorts.
Wu Y; Li Y; Hou Y; Li K; Zhou X
Stat Methods Med Res; 2018 Feb; 27(2):507-520. PubMed ID: 26994213
[TBL] [Abstract][Full Text] [Related]
8. Methods of defining the non-inferiority margin in randomized, double-blind controlled trials: a systematic review.
Althunian TA; de Boer A; Klungel OH; Insani WN; Groenwold RH
Trials; 2017 Mar; 18(1):107. PubMed ID: 28270184
[TBL] [Abstract][Full Text] [Related]
9. Design and analysis of non-inferiority mortality trials in oncology.
Rothmann M; Li N; Chen G; Chi GY; Temple R; Tsou HH
Stat Med; 2003 Jan; 22(2):239-64. PubMed ID: 12520560
[TBL] [Abstract][Full Text] [Related]
10. Are restricted mean survival time methods especially useful for noninferiority trials?
Freidlin B; Hu C; Korn EL
Clin Trials; 2021 Apr; 18(2):188-196. PubMed ID: 33626896
[TBL] [Abstract][Full Text] [Related]
11. Impact of disinvestment from weekend allied health services across acute medical and surgical wards: 2 stepped-wedge cluster randomised controlled trials.
Haines TP; Bowles KA; Mitchell D; O'Brien L; Markham D; Plumb S; May K; Philip K; Haas R; Sarkies MN; Ghaly M; Shackell M; Chiu T; McPhail S; McDermott F; Skinner EH
PLoS Med; 2017 Oct; 14(10):e1002412. PubMed ID: 29088237
[TBL] [Abstract][Full Text] [Related]
12. Exploring how non-inferiority and equivalence are assessed in paediatrics: a systematic review.
Aupiais C; Zohar S; Taverny G; Le Roux E; Boulkedid R; Alberti C
Arch Dis Child; 2018 Nov; 103(11):1067-1075. PubMed ID: 29794107
[TBL] [Abstract][Full Text] [Related]
13. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
Horiguchi M; Hassett MJ; Uno H
Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials.
Trinquart L; Jacot J; Conner SC; Porcher R
J Clin Oncol; 2016 May; 34(15):1813-9. PubMed ID: 26884584
[TBL] [Abstract][Full Text] [Related]
15. Investigating non-inferiority or equivalence in time-to-event data under non-proportional hazards.
Möllenhoff K; Tresch A
Lifetime Data Anal; 2023 Jul; 29(3):483-507. PubMed ID: 36708450
[TBL] [Abstract][Full Text] [Related]
16. Are non-constant rates and non-proportional treatment effects accounted for in the design and analysis of randomised controlled trials? A review of current practice.
Jachno K; Heritier S; Wolfe R
BMC Med Res Methodol; 2019 May; 19(1):103. PubMed ID: 31096924
[TBL] [Abstract][Full Text] [Related]
17. Power and sample size computations in simultaneous tests for non-inferiority based on relative margins.
Dilba G; Bretz F; Hothorn LA; Guiard V
Stat Med; 2006 Apr; 25(7):1131-47. PubMed ID: 16217842
[TBL] [Abstract][Full Text] [Related]
18. Choice of treatment-effect measures when noninferiority margins originally defined in absolute difference translated into relative difference influenced the results of clinical trials.
Abulizi X; Flandre P
J Clin Epidemiol; 2018 Apr; 96():63-72. PubMed ID: 29289760
[TBL] [Abstract][Full Text] [Related]
19. Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated.
Royston P; Parmar MK
BMC Med Res Methodol; 2016 Feb; 16():16. PubMed ID: 26869168
[TBL] [Abstract][Full Text] [Related]
20. Evidence-based sizing of non-inferiority trials using decision models.
Lansdorp-Vogelaar I; Jagsi R; Jayasekera J; Stout NK; Mitchell SA; Feuer EJ
BMC Med Res Methodol; 2019 Jan; 19(1):3. PubMed ID: 30612554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
